
References
- Neal B, et al. N Engl J Med. 2017;377(7):644-57
- Reference 16
The content of this website has been developed by Napp Pharmaceuticals Ltd for healthcare professionals, or patients who have been prescribed Invokana by a UK healthcare professional.
Napp is responsible for the content of this website and is also the copyright owner/authorised user of the content.
Please select an option to continue:
Reporting adverse events
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Napp Pharmaceuticals at drugsafetyuk@napp.co.uk
Reporting adverse events
If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card scheme at www.mhra.gov.uk/yellowcard
By reporting side effects you can help provide more information on the safety of this medicine.
For further information on type 2 diabetes, please visit https://www.diabetes.org.uk/
Reporting adverse events
If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card scheme at www.mhra.gov.uk/yellowcard
By reporting side effects you can help provide more information on the safety of this medicine.
We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
Date of preparation: September 2020 | Job code: UK/INV-18087(4)